

B-Safe User Manual v. 0.0.8 for B-Safe v. 0.1

Alexander Stemke (1), Lars Andersen (1), Oliver Sailer (1), Dunfu Yang (1)
reviewed by Oliver Sailer (1) and Louise Whitehead (1,2)
(1) Boehringer Ingelheim Pharma GmbH & Co. KG
(2) Biostatistics Research Group, Newcastle University, UK

2024-08-18

Contents

1	Introduction	3
2	Using the App	4
2.1	Getting Started	4
3	Data Preparation	6
3.1	Data example	6
3.2	Adding an Arm	7
4	Analysis selection	10
4.1	Select patients with the respective treatment	10
4.2	Select Safety Analysis	10
4.3	Select Safety Topic	11
4.4	Used Seed	11
4.5	Pool by Study	11
5	MAP Prior	13
5.1	MAP Prior: Incidence Proportion	14
5.2	MAP Prior: Exposure-Adjusted Adverse Event Rate	15
6	Robust MAP Prior	17
6.1	Robust MAP Prior: Incidence Proportion	17
6.2	Robust MAP Prior: Exposure-Adjusted Adverse Event Rate	17
7	New Trial Analysis	19
7.1	New Trial Analysis: Incidence Proportions	19
7.2	New Trial Analysis: Exposure-Adjusted Adverse Event Rate	19
8	Decision Making	21
9	Default Comparisons	22
10	Contact	25
	References	25

List of Figures

1	Landing Page	4
2	Creating a Card	4
3	TEAL filtration	7
4	TEAL filtration selection	8
5	Add Arm	9
6	Analysis Selection	10
7	Pool by study	11
8	MAP Prior	13
9	Idle Icon	14
10	Forest Plot - Incidence Proportions	14
11	MAP Prior summary - Incidence Proportions	15
12	Forest Plot - Exposure-Adjusted Adverse Event Rate	15
13	MAP Prior summary - Exposure-Adjusted Adverse Event Rate	16
14	Robust MAP Prior for Incidence Proportion	17
15	Robust MAP Prior for Exposure-Adjusted Adverse Event	18
16	Trial Data Conflict Assessment: Proportions	19
17	Trial Data Conflict Assessment: Rates	20
18	Statistical Inferences: Proportions: Posterior	21
19	Statistical Inferences: Rates: MAP Prior	21
20	Comparison Arm	22
21	Comparison Selection	23
22	Results ready to download	23

List of Tables

1	Variable Columns	5
2	Additional Variables	5
3	Data example	6
4	Data example: Additionl Variables	7
5	Heterogeneity	13
6	Default Values	22

1 Introduction

B-SAFE is an R-Shiny app. The app is an innovative software tool for statistical analysis of adverse event summary data. The app can enhance the descriptive analysis for a current trial with historical information on one or more treatment arms for increased precision. It features a Bayesian Meta-Analytic Predictive (MAP) Prior approach [1] and a robust extension [2], which incorporates historical information for safety analyses on adverse events into safety analyses for a new trial. The use of historical information has been used for efficacy analyses in the past and now being extended to safety analyses.


This user manual details how to use the app. Refer to the Statistical Analysis Plan for the methodology and default values used.

- Coding : Alexander Stemke, Lars Andersen
- Statistical Analysis: Oliver Sailer, Alexander Stemke
- Testing : Lars Andersen, Dunfu Yang
- Support by Steven Brooks, Kevin Kunzmann, Dooti Roy, Christina Schlecker, James O. Turay, Louise Whitehead, Lin Feng Zou

2 Using the App

This section introduces the user to the app and how to prepare the dataset for analysis. From this section on, we will use example data (see table 3) to demonstrate the usage of the entire application. This simple data example is further specified in section 3.1.


Figure 1: Landing Page



You will land on a page similar to this. It is recommended to go through the app from top to bottom. The left and middle panel in fig. 2 correspond to each other. Each bullet point has a section within this manual.

When calculations were performed, you can add a card at the top left corner via **TEAL** and save your results or continue with your settings at a later stage, or log the whole R code used. Click therefore on the + (1.) in figure 2 and name your card.

Figure 2: Creating a Card



2.1 Getting Started

The “Getting Started” page is the first bullet point from the top. It provides an overview of the usage of the app. The app has two main uses:

- A deep dive into a Bayesian MAP Prior analysis of a selected adverse endpoint
- A Posterior Probability analysis to compare a set of adverse events between two treatment arms

Analyses for Incidence Proportions and Exposure-Adjusted Adverse Event Rates (i.e., Incidence Rates) are available.

As you are a user of the app, the first step has already been taken and the app was set up successfully. Therefore, you have to specify a dataset as `.csv` as described in table 1.

You can then jump directly to section Default comparisons section 9 for a summary table with a default analysis.

Table 1: Variable Columns

Variable	Data Type	Description
STUDYID	character/numeric	Study number or name
HIST	boolean	0 for current trial and 1 for historical trial
ARM	character/numeric	Defines the various treatment arms in the respective study
N	numeric	Total number of patients in the respective study
N WITH AE	numeric	Total number of patients for the respective study safety topic who experienced at least one adverse event
SAF TOPIC	character	Describes the type of adverse event. Safety topic will be read in by your dataset, max 30 characters
TOT EXP	numeric	Total exposure time for the respective safety topic: sum of patients treatment exposure period until occurrence of first event.

Note that **TOT EXP** (total exposure time) is only needed for analysis of the Exposure Adjusted Incidence Rate.

Additionally, other variables including Dose, Freq (Frequency), Length (Length of treatment), Treat (Treatment) can be included, as shown in table 2. With these additional variables, subgroup analysis can be done. Note that in Table 2, for variables Freq and Length, the time scale depends on the input and should be consistent throughout the entire dataset. Moreover, further variables could be included (see therefor also the data example 4).

Table 2: Additional Variables

Variable	Data Type	Description
Dose	numeric	Amount/weight of the medication the patient took
Freq(Frequency)	integer	Number of times in the medication was taken by the patient per time unit
Length	integer	Total number of time units the patient was on the treatment
Treat	character	The specific treatment the patient was on

3 Data Preparation

Once you have set up the app, under data preparation the available data is displayed. In the following section 3.1 the dataset will be introduced. Afterwards in section 3.2, the `teal` functionality of data filtration will be briefly introduced, before we prepare an `ARM` to analyze.

3.1 Data example

The following dataset example was generated for this introduction.

Table 3: Data example

	STUDYID	HIST	ARM	N	SAF_TOPIC	N_WITH_AE	TOT_EXP
1	Study#1	1	g1	143	vomitting	34	257.98
2	Study#1	1	g1	120	vomitting	26	338.18
3	Study#1	1	g1	198	vomitting	27	318.65
4	Study#1	1	g1	179	insomnia	36	316.20
5	Study#1	1	g1	200	insomnia	33	334.95
6	Study#1	1	g1	156	insomnia	32	262.24
7	Study#1	0	g1	200	insomnia	34	193.03
8	Study#2	0	g2	109	vomitting	65	334.73
9	Study#2	0	g2	190	vomitting	57	263.33
10	Study#2	0	g2	119	insomnia	55	203.99
11	Study#2	0	g2	124	insomnia	59	273.15
12	Study#2	0	g2	187	vomitting	58	226.69
13	Study#3	1	g3	138	vomitting	58	226.69
14	Study#3	1	g3	114	vomitting	65	334.73
15	Study#3	1	g3	121	vomitting	55	203.99
16	Study#3	1	g3	200	insomnia	59	213.91
17	Study#3	1	g3	183	insomnia	57	263.33
18	Study#3	1	g3	163	insomnia	36	316.20

In brief those three studies are presented. Each study has a `STUDYID` which corresponds in this case with its `ARM`. **Study#1** includes historical (`HIST` = 1) and non historical (`HIST` = 0) information. It only has historical and current information for the Placebo treatment. **Study#2** includes only current data (`HIST` = 0) and **Study#3** only historical (`HIST` = 1).

All additional information, that are not relevant for the `B-SAFE` module, are displayed in table 4. In addition to the predefined additional variables (see table 2), this dataset also includes information on the region of the study.

Table 4: Data example: Additionl Variables

	STUDYID	DOSE	FREQ	LENGTH	TREAT	REGION
1	Study#1	150	2	120	AgentA	Africa
2	Study#1	250	3	240	AgentB	America
3	Study#1	500	1	365	Placebo	Eurasia
4	Study#1	150	3	365	AgentA	Eurasia
5	Study#1	250	1	120	AgentB	Africa
6	Study#1	500	2	240	Placebo	America
7	Study#1	500	2	240	Placebo	Eurasia
8	Study#2	250	1	240	AgentB	America
9	Study#2	500	2	365	Placebo	Africa
10	Study#2	150	3	120	AgentA	Eurasia
11	Study#2	250	1	365	AgentB	America
12	Study#2	150	3	240	AgentA	Eurasia
13	Study#3	150	3	240	AgentA	Africa
14	Study#3	250	1	365	AgentB	America
15	Study#3	500	2	120	Placebo	Africa
16	Study#3	150	2	240	AgentA	Eurasia
17	Study#3	250	3	365	AgentB	America
18	Study#3	500	1	120	Placebo	Africa

It is important to understand, that for the meta-analysis, the data subset which will be used is defined by the variable **ARM**. Accordingly the creation of an arm will be explained next.

3.2 Adding an Arm

Each analysis is performed for the data defined by the variable **ARM**. Before we use the predefined arms, or add a new arm, it is crucial to note, that the filtering via **TEAL** in fig. 3, has to be done, before any arm is created.

By collapsing 1. in fig. 3 you can view your data and by 2. in fig. 3 you can collapse the **TEAL** filtration.

The screenshot displays the TEAL filtration interface. On the left, a sidebar contains navigation options: Data Preparation, Analysis selection, Map Prior, Robust Map Prior, New Trial Analysis, Decision Making, and Default Comparisons. The main area is titled 'Getting Started' and shows a 'Data Preparation' section with a table of data. The table has columns: STUDYID, HIST, ARM, N, SAF_TOPIC, N_WITH_AE, TOT_EXP, DOSE, FREQ, LENGTH, TREAT, and REGION. The data is filtered by 'bsafe_data'. On the right, there is a 'Filter Summary' panel showing 'bsafe_data' with 18/18 observations. Below this, there is a 'Filter Variables' panel with a dropdown menu to 'Add bsafe_data filter'.

Figure 3: TEAL filtration

It is possible to filter for each variable of the dataset. 1. (see fig. 4) select the variable you would like to filter.

In this example we choose the total exposure time and the region. 2. we choose an exposure under 500 and America and Eurasia as a region. Any further arm creation or analysis would be performed on this subset.

For now, we don't need further filtration. This feature is very useful, if you would like to investigate certain subgroup characteristics or see directly a potential arm creation; under 3. it is displayed how many observations remain in this subset. For any further information, please refer to TEALs documentation.

Getting Started

Data Preparation

STUDYID	HIST	ARM	N	SAF_TOPIC	N_WITH_AE	TOT_EXP	DOSE	FREQ	LENGTH	TREAT	REGION
Study#1	1	g1	156	insomnia	32	262.24	500	2	240	Placebo	America
Study#1	0	g1	200	insomnia	34	193.03	500	2	240	Placebo	Eurasia
Study#2	0	g2	119	insomnia	55	203.99	150	3	120	AgentA	Eurasia
Study#2	0	g2	124	insomnia	59	273.15	250	1	365	AgentB	America
Study#2	0	g2	187	vomitting	58	226.69	150	3	240	AgentA	Eurasia
Study#3	1	g3	200	insomnia	59	213.91	150	2	240	AgentA	Eurasia
Study#3	1	g3	183	insomnia	57	263.33	250	3	365	AgentB	America

Analysis selection

Map Prior

Robust Map Prior

New Trial Analysis

Active Filter Summary

Data Name: Obs (7/18)

Active Filter Variables

bsafe_data

TOT_EXP: 192 - 280

REGION: America, Eurasia

Africa (6)

America (6)

Eurasia (6)

Add Filter Variables

Add bsafe_data filter

Select variable to filter

Figure 4: TEAL filtration selection

Starting with our original dataset we will now create a data subset called an arm, which we will investigate further.

▼ Data Preparation

Select the columns

1. DOSE TREAT

Select the forms of DOSE

2. 500

Select the forms of TREAT

3. Placebo

4. Placebo500 5. +

Placebo500 6. ✕

Figure 5: Add Arm

Starting with 1. (see fig. 5) select the variables you are interested in. In this example we choose DOSE and TREAT. 2. and 3. choose the variables characteristics. In this case, we are interested to borrow information from the Placebo treatments. In general it is discouraged to borrow information from treatment arms that are not Placebo or standard of care. 4. you name the arm, and to you add the arm. Using 6. a created arm can also be deleted again. Any errors that might occur (e.g. trying to give 2 times the same name), an error will be displayed at the bottom right of your screen.

In this case the subset of dose 500 and Placebo treatment is identical, but especially with an increasing number of studies to borrow from, it is better to ensure your correct choices. On our example **ARM: Placebo500** we will now perform any further analysis.

4 Analysis selection

The filtered data is then displayed on the right hand side of the screen when 1. in figure 6 is collapsed.

The screenshot shows the 'Report previewer' interface for teal.modules.bsaf. On the left, the 'Analysis selection' section is expanded, showing options for 'Select patients with the respective treatment' (Placebo500), 'Select safety analysis' (Incidence proportion), 'Select safety topic' (vomitting), 'Used seed' (1723640473), and a checked 'Pool by study' option. On the right, the 'Analysis selection' section is collapsed, and a table of data is displayed. The table has columns 'STUDYID', 'N', and 'N_WITH_AE'. The data rows are Study#1 (198, 27), Study#2 (190, 57), and Study#3 (121, 55). Red circles and numbers 1, 2, and 3 highlight the 'Analysis selection' section, the 'Select patients with the respective treatment' dropdown, and the data table, respectively.

STUDYID	N	N_WITH_AE
Study#1	198	27
Study#2	190	57
Study#3	121	55

Figure 6: Analysis Selection

Under 2. in fig. 6 we have several options, we will explain each of them next.

4.1 Select patients with the respective treatment

If there are different treatment options in the uploaded dataset file, and you have created different ARMS you can 2. choose a specific ARM from the drop-down menu in figure 6. In this case we choose our created ARM Placebo500. g1 would not be a wise choice, it includes different treatments.

4.2 Select Safety Analysis

The drop-down menu in figure 6 provides two analyses options to choose from:

- Incidence Proportion: sometimes known as Adverse Event Rate which describes the proportion of patients with at least one of the Adverse Event of interest in our trial, i.e., $Incidence\ Proportion = \frac{\sum N_WITH_AE}{\sum N}$ where $\sum N_WITH_AE$ = total number of patients with AE and $\sum N$ = total number of patients.

Incidence proportion can also be described as the estimated probability of a patient having one or more AEs during the specific period.

- Exposure Adjusted Adverse Event Rate: sometimes referred to as Incident rate, which describes the incident rate of AEs per patient per time unit assuming a constant hazard rate. This could be interpreted as the number of patients having one or more adverse events per unit time under assumption of constant risk over the observational period. $Exposure\ Adjusted\ Event\ Rate = \frac{\sum N_WITH_AE}{\sum t_i}$ where $\sum N_WITH_AE$ = number of subjects who had at least one AE, t_i = subject i 's total exposure time to first AE or censoring.

The choice of Safety Analysis option is based on the need of the user. Later section will be divided into subsection to give a proper insight to the use of the app.

4.3 Select Safety Topic

The user should select a safety topic (AE endpoint) that a (robust) MAP Prior will explore from the drop-down menu in Figure 6. The filtered data will be displayed on the right hand side of the screen.

By default, the first AE endpoint (ordered alphabetically) will be selected and displayed. In our example we choose also vomiting.

4.4 Used Seed

The user can manually set the seed for reproducibility of results of the Markov Chain Monte Carlo simulations and other random draws (see figure 6). Be aware that reproducibility is only guaranteed, while you are in the same session. For more information, please refer to the statistical analysis plan.

By default, a seed is given, but you can always overwrite the seed.

4.5 Pool by Study

If the defined treatment arm includes subsets within the trial, e.g., several different doses, the user can choose to pool these together or keep them separated for the purpose of MAP Prior analysis. The default option is to pool the studies together (see 1. figure 7).




Figure 7: Pool by study

As can be seen in 2. the sum over the study is taken, if the studies won't be pooled, each subgroup is treated as a own group within the hierarchical model. For the demonstration we changed the ARM to g1. If we 3.

select no pooling we get the three different subgroups from different regions with different frequency.
For the reminder of the demonstration using Placebo500, there is no difference whether we pool or not.

5 MAP Prior

Figure 8: MAP Prior

The figure shows two panels of a software interface. The left panel is titled 'MAP Prior' and contains three sections: 'Between-Trial Heterogeneity Prior Distribution' with a dropdown set to 'Half-normal', a text box explaining that $\frac{\tau}{\sigma}$ controls the amount of historical borrowing, and a dropdown set to 'Large'. Below this is the 'Effective Sample Size Method' dropdown set to 'Expected Local Information Ratio'. At the bottom is a button labeled 'Update Map Priors'. The right panel is titled 'Model Estimates' and contains a message: 'Displayed are the point estimates for the mean (dots) and their resp highlighted part displays the 95% credible interval (CrI) for the mean'. Below this is a red circle around the text 'Selection or data has changed please update Map Prior'.

1. **Map Prior**

2. **Between-Trial Heterogeneity Prior Distribution**

3. **Update Map Priors**

4. **Selection or data has changed please update Map Prior**

The MAP Prior as proposed (see [1]) is estimated using a meta-analytic predictive model which accounts for the between-trial heterogeneity.

First collapse the section under 1. in fig. 8. Under 2. you have different options. The B-SAFE module uses the Half-normal distribution as a prior distribution for the between trial heterogeneity parameter τ as seen in fig. 8 which is a special case of the normal distribution that is truncated to values greater than or equal to zero.

To control the amount of information borrowed, the drop-down menu in fig. 8 gives you control of how much historical information to borrow using the recommendation (see [3]) as shown in Table 5. Generally, with larger heterogeneity less information will be borrowed.

Heterogeneity	τ/σ
small	0.0625
moderate	0.125
substantial	0.25
large	0.5
very large	1

Table 5: Heterogeneity

The amount of information to be borrowed depends on the confidence the user has on the similarity between the new and historical data. In the app, the (default) hyperparameter for τ representing between-trial heterogeneity has been set to Large [4].

For the Expected Sample Size method, the Expected Local Information Ratio proposed in [5] is used. This is due to its predictive consistency.

In fig. 8 the most important button is 3. For any relevant changes, the MCMC sample has to be calculated again. If no MAP prior was calculated, or any changes where done, then 4. is displayed.

For our example we use the default settings and continue with the incidence proportions and will investigate the exposure adjusted adverse event rate.

After 3. Updating the MAP prior, a small idle token (see fig. 9) will appear on the bottom right corner and then the results instead of 3.

Figure 9: Idle Icon



5.1 MAP Prior: Incidence Proportion

Figure 10 is the forest plot displays the frequentist estimates for the strata (dashed lines) and the lower part shows the mean distribution and the MAP prior distribution of the mean. The forest plot gives a graphical insight on the similarity of the studies.

Figure 10: Forest Plot - Incidence Proportions





Figure 11, shows the density curve and summary statistics for the MAP Prior.

Figure 11: MAP Prior summary - Incidence Proportions



The MAP prior for the incidence Proportion is generated by MCMC samples and then approximated by mixture of three Beta distributions (see figure 11).

5.2 MAP Prior: Exposure-Adjusted Adverse Event Rate

Figure 12 is the forest plot displays the frequentist estimates for the strata (dashed lines) and the lower part shows the mean distribution and the MAP prior distribution of the mean. The forest plot gives a graphical insight on the similarity of the studies.

Figure 12: Forest Plot - Exposure-Adjusted Adverse Event Rate





Figure 13, shows the density curve and summary statistics for the MAP Prior.

Figure 13: MAP Prior summary - Exposure-Adjusted Adverse Event Rate



The MAP prior for the Exposure-Adjusted Event Rate is estimated as the log hazard rate using the asymptotic normal distribution. The MAP Prior for the log hazard is approximated by mixture of three normal distributions (see fig 13).

6 Robust MAP Prior

To protect against prior-data conflict, MAP priors should be robustified [6]. This adds a weakly informative component to the (informative) MAP prior distribution, such that the more the historical data differs from the observed data, the more robust MAP Prior will weigh down/discount the information from the historical data thus preventing prior data conflict. The default prior weight on the weakly informative component has been set to 0.2 (20%) discounting factor.

Depending on the expected comparability between the historical data and the observed data, the user can choose the weight of the weakly informative robust prior component. The smaller the weakly-informative prior weight figure, the more confidence the user has in the historical data and the less discount in the historical data.

A graph depicting both the MAP Prior (dotted in red) and Robust MAP Prior (dashed in blue) is the generated on the right hand side of the page.

6.1 Robust MAP Prior: Incidence Proportion

For incidence proportion analysis, the uninformative mean is set to 50% and thus a Beta(1,1) distribution is chosen as the weakly-informative prior.

By adding the non-informative part (1.), now the robustified MAP prior is approximated by four Beta distributions. The former three Beta component were down weighted so that the effective sample size is now reduced. The prior weight corresponds with the weight for the non-informative component (2.).

Here note that the mode/peak of the distribution you see in the plot might be different from the mean shown in the table underneath the plot in that both the prior and robustified prior are mixture of multiple densities.




Figure 14: Robust MAP Prior for Incidence Proportion

6.2 Robust MAP Prior: Exposure-Adjusted Adverse Event Rate

For exposure-adjusted adverse event rate, a weakly-informative prior mean (hazard ratio) as in figure 15 is also selected for the robust MAP prior to be calculated and the mean value is supposed to be chosen by the user. Note that if the SD for the robustified MAP prior is larger than 1, this means that the robustification turns to be informative so that we suggest not to borrow any information.




Figure 15: Robust MAP Prior for Exposure-Adjusted Adverse Event

For the robustification of the Exposure-Adjusted Adverse Event Rate, you need to choose a prior weight (1.) as well as a prior mean (2.). It is recommended to select an non-informative mean. In this case, we just used the default value 0.5, which corresponds to 3. ($\log(0.5) = -0.69$). In the summary table (4.) only on the $\log(\text{hazard rates})$ the ESS (or rather ENE: Effective Number of Events) is displayed.

7 New Trial Analysis

The Robust MAP Prior obtained (see section 6) is then updated with by the input via the sliders. The non-historical information from the dataset is not used here. This provides a Bayesian Posterior. The summary of the Robust MAP Prior, Likelihood and Posterior and their densities are displayed. The generated graph allows to asses a potential prior data conflict.

7.1 New Trial Analysis: Incidence Proportions

For the new trial analysis you need to select (1.) the number of new patients (max. 200). Also (2.) the number of patients with at least one event of interest observed has to be specified. This number cannot exceed the number of patients.




Figure 16: Trial Data Conflict Assessment: Proportions

The Robust MAP Prior (red dotted) describes the density for the borrowed historical information.

The Likelihood (green dashed) describes a density that would describe current data, using the maximum likelihood estimation for an one component Beta distribution.

The Posterior distribution (blue dot-dash) describes the synthesis of historical prior and the current data from which decisions can then be made.

For our data example, no events observed would be a prior data conflict. In consequence, the mean is only slightly drawn towards the MAP prior. In this case you could consider to increase the robustification (see section 6).

7.2 New Trial Analysis: Exposure-Adjusted Adverse Event Rate

For the new trial analysis you need to select (1.) the number of new observed events (max. 200). Also (1.) cumulative total exposure time of patients with at least one event of interest observed has to be specified (max. 1000).




Figure 17: Trial Data Conflict Assessment: Rates

The Robust MAP Prior (red dotted) describes the density for the borrowed historical information.

The Likelihood (green dashed) describes a density that would describe current data, using the maximum likelihood estimation for an one component Beta distribution.

The Posterior distribution (blue dot dash) describes the synthesis of historical prior and the current data from which decisions can then be made.

For our data example, no events observed would be a prior data conflict. In consequence, the mean is only slightly drawn towards the MAP prior. In this case you could consider to increase the robustification (see section 6).

For the ESS only the value for the robustified MAP prior is displayed.

8 Decision Making

The Decision Making section allows statistical inferences to be made based on the Likelihood, MAP Prior, Robust MAP Prior and the Posterior distribution. These options can be obtained by assessing the drop-down menu (1.) in figure 18 and 19 respectively. Note that the inference based on the likelihood is with respect to the data from your new trial analysis input (see section 7), in contrast to which based on the prior/posterior are with respect to the underlying parameter.

The colored area under the curve describes the probability for the value to be within the defined boundaries.




Figure 18: Statistical Inferences: Proportions: Posterior

For the Exposure-Adjusted Adverse Event Rate




Figure 19: Statistical Inferences: Rates: MAP Prior

Probabilities can be obtained for values exceeding/not-exceeding/between limits that can be specified using the slider as shown in Figure 18 or 19 on the left hand-side of the page.

Additionally, inferences are made with 90%, 95% and 99% probabilities as shown in figure 18 or 19.

9 Default Comparisons

Summary tables are produced that contain the posterior probability analysis for all the adverse events in the uploaded dataset. There are also tables for the Incidence Proportion and Exposure-adjusted Adverse Event Rates for all the adverse events in the dataset.

The values that are used in exploring the uploaded dataset has no effect in generating the summary tables of the analysis as the default settings are used. For more information regarding the default setting (tab. 6), see the statistical analysis plan, it can be accessed via the Getting Started section.

Table 6: Default Values

	Default	Proportions	Rates
1	family	binomial	poisson
2	iter	6000	6000
3	warmup	2000	2000
4	thin	4	4
5	chains	4	4
6	gMAP: tau.dist	HalfNormal	HalfNormal
7	beta.prior	2	1
8	Large Heterogeneity	1	0.5
9	Robust Weight	0.2	0.2
10	Robust Mean	0.5	$\log(N \text{ WITH AE}/\text{TOT EXP})$
11	Reference standard deviation		1
12	No historical information	Beta(1,1)	Normal($\log(N \text{ WITH AE NEW}/\text{TOT EXP NEW}), 1)$
13	No current data	Robustified MAP Prior as Posterior	Robustified MAP Prior as Posterior

Summary tables are generated for all adverse events in the dataset and not only those that were explored.

For this reason we use our data example to create a new arm (see section 3.2)




Figure 20: Comparison Arm

Therefore, we selected only current information of Agent A. If you accidentally forget to enter a new arm name, as seen on the left of figure 20 you get an error message on the bottom right.

Figure 21: Comparison Selection

You can choose up to 5 different comparison groups. By choosing Show comparison (see fig. 21), you have to select the arms, that shall build the groups from which you borrow. The slider can be moved based on the number of comparisons you would like to perform. For example you could also create an arm that includes Placebo dose 250, and add it to you selection for the control arm.

Once the Treatment and Control arms has been selected, click the Submit button. You then have to wait for the simulation/calculation to be completed. Depending on the number of Adverse Event Endpoints and the number of comparisons done, this simulation process can take some time.

Once the simulation is completed (see fig. 22), the chosen comparisons are then displayed by a pop-up and you can download the PDF on the right-hand side on the page.

Figure 22: Results ready to download

For each comparison, five different tables are produced:

- Table 1 lists the different trials that make up each arm (Treatment and Control) of the comparison.
- Table 2 indicates the number of patients that experienced each Adverse Event r , the total number of patients n , and the proportion (%) of patients with AE in the population. Posterior summary shows the Posterior Distribution mean, median and the 95% credible interval.

- Table 3 estimates the Risk Difference and the Risk Ratio calculated from the number of patients with the event r and the total number of patient n (Incidence Proportion). Posterior summary shows the Posterior Distribution mean, median and 95% credible interval.
- Table 4 shows the Exposure-Adjusted Adverse Event rate, the rate of patients with event per patient year at risk. Naive estimates show the (pooled) number of patients with event r , divided by the (pooled) total exposure time. Posterior summary shows the Posterior Distribution mean, median and 95% credible interval.
- Table 5 estimates the Risk Difference and Risk Ratio calculated from (pooled) number of patients with event r and (pooled) number of patients (Exposure-Adjusted Adverse Event Rate). Posterior summary shows the Posterior Distribution mean, median and 95% credible interval.

10 Contact

This app is not validated. However, extensive structural and statistical testing is implemented. See under section 2.1 the documentation for different tests.

For questions and feedback please contact:

- Alexander Stemke alexander.stemke@boehringer-ingelheim.com GitHub: AStemke
- Dunfu Yang dunfu.yang@boehringer-ingelheim.com

References

- [1] NEUENSCHWANDER, B., CAPKUN-NIGGLI, G., BRANSON, M. and SPIEGELHALTER, D. J. (2010). Summarizing historical information on controls in clinical trials. *Clinical Trials* **7** 5–18.
- [2] SCHMIDLI, H., GSTEIGER, S., ROYCHOUDHURY, S., O’HAGAN, A., SPIEGELHALTER, D. and NEUENSCHWANDER, B. (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. *Biometrics* **70** 1023–32.
- [3] WEBER, S., LI, Y., III, J. W. S., KAKIZUME, T. and SCHMIDLI, H. (2021). Applying meta-analytic-predictive priors with the r bayesian evidence synthesis tools. *Journal of Statistical Software* **100**.
- [4] GHADDESI, M., TANG, R., ZHOU, J., LIU, R., WANG, C., TOYOIZUMI, K., MEI, C., ZHANG, L., DENG, C. Q. and BECKMAN, R. A. (2020). A roadmap to using historical controls in clinical trials – by drug information association adaptive design scientific working group(Dia-adsWG). *Orphanet Journal of Rare Diseases* **15** 69.
- [5] NEUENSCHWANDER, B., WEBER, S., SCHMIDLI, H. and O’HAGAN, A. (2020). Predictively consistent prior effective sample sizes. *Biometrics* **76** 578–87.
- [6] SCHMIDLI, H., GSTEIGER, S., ROYCHOUDHURY, S., O’HAGAN, A., SPIEGELHALTER, D. and NEUENSCHWANDER, B. (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. *Biometrics* **70** 1023–32.